Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BNGO Bionano Genomics Inc
- Stocks
- Healthcare
- NASDAQ: BNGO
Price (delayed)
$3.79
Market cap
$12.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$54.48
Enterprise value
$27.54M
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for
Highlights
The EPS has soared by 85% YoY and by 38% QoQ
BNGO's quick ratio has surged by 78% since the previous quarter and by 17% year-on-year
Bionano Genomics's gross profit has plunged by 95% YoY but it has increased by 30% from the previous quarter
BNGO's gross margin has dropped by 94% year-on-year but it is up by 42% since the previous quarter
Bionano Genomics's revenue has decreased by 24% YoY and by 8% QoQ
Key stats
What are the main financial stats of BNGO
Market
Valuations
Earnings
Shares outstanding
3.36M
Market cap
$12.75M
Enterprise value
$27.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.24
Price to sales (P/S)
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.97
Revenue
$28.46M
Gross profit
$494,000
Operating income
-$81.33M
Net income
-$83.7M
EBIT
-$83.64M
EBITDA
-$70.02M
Free cash flow
-$43.63M
Per share
Balance sheet
Liquidity
EPS
-$54.48
EPS diluted
-$54.48
Free cash flow per share
-$16.2
Book value per share
$16.03
Revenue per share
$10.57
TBVPS
$26
Total assets
$78.41M
Total liabilities
$30.23M
Debt
$18.42M
Equity
$48.19M
Working capital
$18.52M
Debt to equity
0.38
Current ratio
1.7
Quick ratio
1.23
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
-246%
Gross margin
1.7%
Net margin
-294%
Operating margin
-285.7%
Return on assets
-90%
Return on equity
-157.3%
Return on invested capital
-144.8%
Return on capital employed
-160.8%
Return on sales
-293.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNGO stock price
How has the Bionano Genomics stock price performed over time
Intraday
-3.56%
1 week
-1.19%
1 month
-6.42%
1 year
-94.31%
YTD
-78.09%
QTD
35.84%
Financial performance
How have Bionano Genomics's revenue and profit performed over time
Revenue
$28.46M
Gross profit
$494,000
Operating income
-$81.33M
Net income
-$83.7M
Gross margin
1.7%
Net margin
-294%
Bionano Genomics's gross profit has plunged by 95% YoY but it has increased by 30% from the previous quarter
BNGO's gross margin has dropped by 94% year-on-year but it is up by 42% since the previous quarter
The company's net income has surged by 63% YoY and by 25% QoQ
BNGO's operating income has soared by 61% YoY and by 22% from the previous quarter
Price vs fundamentals
How does BNGO's price correlate with its fundamentals
Growth
What is Bionano Genomics's growth rate over time
Valuation
What is Bionano Genomics stock price valuation
P/E
N/A
P/B
0.24
P/S
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.97
The EPS has soared by 85% YoY and by 38% QoQ
BNGO's price to book (P/B) is 92% lower than its 5-year quarterly average of 3.0 and 60% lower than its last 4 quarters average of 0.6
BNGO's equity is down by 42% YoY but it is up by 36% from the previous quarter
The P/S is 99% below the 5-year quarterly average of 33.6 and 55% below the last 4 quarters average of 0.8
Bionano Genomics's revenue has decreased by 24% YoY and by 8% QoQ
Efficiency
How efficient is Bionano Genomics business performance
The ROS has soared by 51% YoY and by 19% QoQ
Bionano Genomics's ROIC has increased by 31% YoY and by 15% from the previous quarter
Bionano Genomics's return on assets has increased by 18% YoY and by 9% QoQ
Bionano Genomics's return on equity has increased by 13% QoQ and by 11% YoY
Dividends
What is BNGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNGO.
Financial health
How did Bionano Genomics financials performed over time
BNGO's total assets is 159% greater than its total liabilities
BNGO's quick ratio has surged by 78% since the previous quarter and by 17% year-on-year
BNGO's current ratio has surged by 60% since the previous quarter and by 16% year-on-year
Bionano Genomics's debt is 62% less than its equity
Bionano Genomics's debt has plunged by 51% YoY and by 33% from the previous quarter
The debt to equity has dropped by 51% since the previous quarter and by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.